Identifying biologic-eligible patients, Hurley Stage 2 or 3, in HS patients

Challenge

Understanding the specific patient characteristics that show which HS patients are likely to respond to biologic therapy

Solution

• Leverage OM1 linked, clinical EMR and claims data that includes Hurley stage, steroid dosing and exposure
• OM1 data also includes extracted disease activity descriptors for body location and use of bDMARDs